# Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

> **NCT05042258** · PHASE4 · RECRUITING · sponsor: **Northwestern University** · enrollment: 40 (estimated)

## Conditions studied

- Atopic Dermatitis
- Sleep Disturbance

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT05042258
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-12
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05042258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05042258, "Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05042258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*